Elekta AB (publ) (EKTAF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Elekta AB (publ) (EKTAF) with AI Score 47/100 (Weak). Elekta AB (publ) is a medical technology company specializing in clinical solutions for cancer and brain disorders. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Elekta AB (publ) (EKTAF) Healthcare & Pipeline Overview
Elekta AB (publ) is a Swedish medical technology firm providing radiation therapy and neurosurgery solutions globally. Its diverse product portfolio, including linear accelerators and Gamma Knife systems, addresses cancer and brain disorders. With a focus on innovation and comprehensive care services, Elekta serves a critical role in the medical device industry.
Investment Thesis
Elekta AB (publ) presents a mixed investment case. While the company operates in a growing market for cancer and brain disorder treatments, its negative profit margin of -0.2% and ROE of -0.4% raise concerns about profitability. The company's high debt-to-equity ratio of 90.91 may limit financial flexibility. Growth catalysts include the expansion of its Elekta Unity and Elekta Harmony product lines, as well as the increasing demand for advanced radiation therapy solutions. However, investors should closely monitor the company's ability to improve profitability and manage its debt levels. The company's beta of 1.09 indicates market correlation.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $2.37B reflects Elekta's position in the medical technology industry.
- Gross Margin of 38.5% indicates the profitability of Elekta's products before operating expenses.
- Debt-to-Equity Ratio of 90.91 suggests a leveraged capital structure, requiring careful monitoring.
- Negative Profit Margin of -0.2% signals challenges in achieving overall profitability.
- Beta of 1.09 indicates that the stock's price is slightly more volatile than the market.
Competitors & Peers
Strengths
- Comprehensive product portfolio in radiation therapy and neurosurgery.
- Global presence with operations in multiple regions.
- Strong brand reputation and established customer relationships.
- Innovative technology, including Elekta Unity and Gamma Knife systems.
Weaknesses
- Negative profit margin and ROE.
- High debt-to-equity ratio.
- Dependence on capital equipment sales.
- Exposure to regulatory and reimbursement risks.
Catalysts
- Ongoing: Expansion of Elekta Unity and Elekta Harmony product lines.
- Ongoing: Growth in stereotactic radiosurgery and brachytherapy markets.
- Ongoing: Increasing demand for veterinary radiation therapy solutions.
- Ongoing: Expansion of Elekta Care support services.
Risks
- Potential: Competition from established players like Varian and Accuray.
- Potential: Technological obsolescence.
- Potential: Economic downturns affecting capital equipment spending.
- Potential: Changes in healthcare regulations and reimbursement policies.
- Ongoing: Negative profit margin and ROE.
Growth Opportunities
- Expansion of Elekta Unity: Elekta Unity, with its anatomy-specific MR imaging, represents a significant growth opportunity. The global MRI market is projected to reach $7.3 billion by 2027, driven by advancements in imaging technology and increasing demand for diagnostic accuracy. Elekta can leverage this trend by expanding the adoption of Elekta Unity in cancer centers worldwide, offering enhanced treatment precision and personalized care. Timeline: Ongoing.
- Adoption of Elekta Harmony: Elekta Harmony is designed to address a wide range of radiotherapy needs, from simple to complex cases. The global radiotherapy market is expected to reach $8.7 billion by 2028, fueled by the rising incidence of cancer and advancements in treatment techniques. By promoting Elekta Harmony as a versatile and efficient solution, Elekta can capture a larger share of this expanding market. Timeline: Ongoing.
- Growth in Stereotactic Radiosurgery: Elekta's stereotactic radiosurgery products, including the Elekta Esprit Gamma Knife system, offer a non-invasive alternative for treating brain disorders. The global stereotactic radiosurgery market is projected to grow, driven by the increasing demand for minimally invasive procedures and technological advancements. Elekta can capitalize on this trend by expanding the availability of its Gamma Knife systems and treatment planning software. Timeline: Ongoing.
- Brachytherapy Solutions: Elekta's brachytherapy products, such as Elekta Studio and Elekta Flexitron, provide precise and targeted radiation therapy. The global brachytherapy market is expected to grow, driven by the increasing demand for localized cancer treatments and technological advancements. Elekta can strengthen its position by promoting its brachytherapy solutions as an effective and efficient treatment option. Timeline: Ongoing.
- Elekta Care Services: Elekta Care support services, including training, a self-help center, and predictive maintenance, offer a recurring revenue stream and enhance customer loyalty. The global healthcare support services market is expected to grow, driven by the increasing demand for comprehensive and integrated solutions. By expanding its Elekta Care offerings, Elekta can generate additional revenue and strengthen its relationships with healthcare providers. Timeline: Ongoing.
Opportunities
- Expansion of Elekta Unity and Elekta Harmony product lines.
- Growth in stereotactic radiosurgery and brachytherapy markets.
- Increasing demand for veterinary radiation therapy solutions.
- Expansion of Elekta Care support services.
Threats
- Competition from established players like Varian and Accuray.
- Technological obsolescence.
- Economic downturns affecting capital equipment spending.
- Changes in healthcare regulations and reimbursement policies.
Competitive Advantages
- Proprietary technology in radiation therapy and neurosurgery.
- Established relationships with hospitals and cancer centers.
- Comprehensive service offerings, including training and maintenance.
- Strong brand reputation in the medical technology industry.
About EKTAF
Elekta AB (publ), founded in 1972 and headquartered in Stockholm, Sweden, is a medical technology company dedicated to providing innovative clinical solutions for treating cancer and brain disorders. The company operates across the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions. Elekta's core offerings include linear accelerators and radiation therapy products designed to deliver precise and effective treatment. Key products include Elekta Unity, which integrates MR imaging for anatomy-specific targeting; Elekta Evo, enabling adaptive radiation therapy; Elekta Versa HD, a solution for brain metastases; Elekta Harmony; and Elekta Infinity, catering to a wide range of radiotherapy needs. In addition to linear accelerators, Elekta provides stereotactic radiosurgery products such as the Elekta Esprit Gamma Knife system and Leksell GammaPlan treatment planning software. The company also offers brachytherapy solutions, including Elekta Studio for image-guided brachytherapy and Elekta Flexitron afterloader for precise workflow execution. Elekta's product portfolio extends to neurosurgery with the Leksell Vantage Stereotactic System and personalized cancer care solutions like Elekta Kaiku. Furthermore, the company provides veterinary radiation therapy solutions, expanding its reach beyond human medicine. Elekta complements its product offerings with comprehensive support services under the Elekta Care umbrella, including training, a self-help center, and predictive maintenance through Elekta Intellimax. This holistic approach positions Elekta as a key player in the global medical technology market, committed to advancing cancer and brain disorder treatments.
What They Do
- Develops and markets linear accelerators for radiation therapy.
- Offers stereotactic radiosurgery systems, including the Gamma Knife.
- Provides brachytherapy solutions for targeted radiation treatment.
- Manufactures neurosurgery products, such as the Leksell Vantage Stereotactic System.
- Offers oncology software suites for treatment planning and management.
- Provides comprehensive support services, including training and maintenance.
- Develops veterinary radiation therapy solutions.
Business Model
- Sells linear accelerators and related radiation therapy equipment to hospitals and cancer centers.
- Generates revenue from stereotactic radiosurgery systems and treatment planning software.
- Offers brachytherapy solutions and associated services.
- Provides maintenance and support services for its installed base of equipment.
Industry Context
Elekta AB (publ) operates within the medical device industry, specifically focusing on radiation therapy and neurosurgery solutions. The industry is driven by increasing cancer prevalence, technological advancements, and an aging global population. Competition includes companies like Varian Medical Systems (VAR), Accuray Incorporated (ARAY), and Siemens Healthineers (SIEGY), each vying for market share with innovative treatment solutions. The market for radiation therapy equipment is expected to grow, driven by demand for precision and minimally invasive treatments.
Key Customers
- Hospitals and cancer centers.
- Neurosurgery clinics.
- Veterinary clinics.
- Research institutions.
Financials
Chart & Info
Elekta AB (publ) (EKTAF) stock price: Price data unavailable
Latest News
-
European Growth Stocks With Insider Ownership Up To 20%
Simply Wall St. · Feb 16, 2026
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Friday
· Feb 28, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EKTAF.
Price Targets
Wall Street price target analysis for EKTAF.
MoonshotScore
What does this score mean?
The MoonshotScore rates EKTAF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
EKTAF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Elekta AB (publ) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Lower liquidity compared to major exchanges.
- Potential for wider bid-ask spreads.
- Higher risk of fraud or manipulation.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and track record.
- Evaluate the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Assess the company's liquidity and trading volume.
- Consult with a financial advisor or conduct thorough research.
- Confirm the company's registration and good standing with regulatory authorities.
- Established history since 1972.
- Global operations across multiple regions.
- Presence in the medical technology industry.
- Partnerships with hospitals and cancer centers.
- Development of innovative products like Elekta Unity and Gamma Knife systems.
What Investors Ask About Elekta AB (publ) (EKTAF)
What does Elekta AB (publ) do?
Elekta AB (publ) is a medical technology company that provides clinical solutions for treating cancer and brain disorders. The company's core business revolves around developing, manufacturing, and marketing radiation therapy and neurosurgery equipment. Its product portfolio includes linear accelerators, stereotactic radiosurgery systems (like the Gamma Knife), brachytherapy solutions, and oncology software. Elekta's solutions are used in hospitals, cancer centers, and neurosurgery clinics worldwide, positioning the company as a key player in the global medical technology market focused on oncology and neurology treatments.
What do analysts say about EKTAF stock?
AI analysis is pending for EKTAF. Generally, analyst opinions on medical technology companies like Elekta AB (publ) consider factors such as revenue growth, profitability, and product innovation. Key valuation metrics include price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-EBITDA (EV/EBITDA). Growth considerations often focus on the adoption of new technologies, expansion into emerging markets, and the company's ability to maintain a competitive edge. However, without specific analyst reports, a detailed assessment is not possible.
What are the main risks for EKTAF?
Elekta AB (publ) faces several risks inherent to the medical technology industry. Competition from larger players like Varian and Accuray poses a constant threat. Technological obsolescence is a concern, requiring continuous investment in research and development. Economic downturns can impact capital equipment spending by hospitals and clinics, affecting sales. Changes in healthcare regulations and reimbursement policies can also affect the demand for Elekta's products. The company's negative profit margin and high debt-to-equity ratio add to the financial risks.
What are the key factors to evaluate for EKTAF?
Elekta AB (publ) (EKTAF) currently holds an AI score of 47/100, indicating low score. Key strength: Comprehensive product portfolio in radiation therapy and neurosurgery.. Primary risk to monitor: Potential: Competition from established players like Varian and Accuray.. This is not financial advice.
How frequently does EKTAF data refresh on this page?
EKTAF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven EKTAF's recent stock price performance?
Recent price movement in Elekta AB (publ) (EKTAF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Comprehensive product portfolio in radiation therapy and neurosurgery.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider EKTAF overvalued or undervalued right now?
Determining whether Elekta AB (publ) (EKTAF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying EKTAF?
Before investing in Elekta AB (publ) (EKTAF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be outdated.
- OTC market data may be less reliable than major exchanges.